1. Background {#sec0005}
=============

Reliable rapid diagnostic tools can generally help confirm infection in suspected cases during disease outbreaks, and therefore they can help improve hygiene management and prevent the further spread of the disease. The most extensively used tools are rapid antigen detection tests (RDTs) [@bib0130], [@bib0135]. RDTs are simple, fast (10--15 min), and suitable for point-of-care screening. Nevertheless, many reports stress the limited sensitivity and specificity of RDTs [@bib0135], [@bib0140], [@bib0145], [@bib0150], and RDT results are yet to be confirmed by real-time polymerase chain reaction (PCR).

Currently, real-time PCR is the standard of molecular diagnosis [@bib0155], [@bib0160], [@bib0165]. Samples are sent to regional or central laboratories for testing. Alternatively, a mobile real-time PCR system can be used at an outbreak site for the detection of pathogen nucleic acid. However, mobile real-time PCR devices are large, expensive, and complex. In addition, the test run time varies between 50 and 90 min [@bib0170].

For rapid wide-scale testing, robust easy-to-use molecular test systems that can be applied in the field provide a big advantage, as they allow rapid on-site nucleic acid detection at the point of need. Smart mobile assays should be able to discover silent or clinical relevant cases even in rural areas with low infrastructure.

Recombinase polymerase amplification (RPA) [@bib0175] represents an alternative technology to the real-time PCR. RPA is an isothermal DNA amplification and detection technology. This assay is rapid (2--15 min) and operated via a compact portable device (i.e., a tube scanner, 19 cm × 17.5 cm) [@bib0180], [@bib0185], [@bib0190], [@bib0195].

2. Objectives {#sec0010}
=============

In this study, reverse transcription RPA (RT-RPA) assays were developed for the detection of avian influenza A (H7N9) virus. Moreover, "Diagnostics-in-a-Suitcase" (DiaS) was established in order to facilitate its use at the site of an outbreak.

3. Study design {#sec0015}
===============

3.1. Viral nucleic acid and oligonucleotides {#sec0020}
--------------------------------------------

The Quality Control for Molecular Diagnostics, Glasgow, Scotland, UK; the Landesgesundheitsamt Niedersachsen, Hanover, Germany; and Robert Koch Institute, Berlin, Germany, provided the human viruses and viral nucleic acids ([Table 1](#tbl0005){ref-type="table"} ) used in this study. The avian respiratory viral nucleic acid panel ([Table 1](#tbl0005){ref-type="table"}) was provided by the Friedrich-Loeffler-Institute, Greifswald-Insel Riems, Germany.Table 1List of viral nucleic acids. H7N9 RT-RPA assays detected only H7 and N9 RNA but not other nucleic acids of viruses causing respiratory manifestations.Viral nucleic acidH7 RT-RPA assayN9 RT-RPA assay**Human respiratory viruses**Coronavirus 229E, NL63, and OC43−−SARS coronavirus−−MERS coronavirus−−Influenza A (H1N1 pdm09)−−Influenza A (H3N2)−−Influenza A (H5N1)−−Influenza A (H1N1 H275Y)−−Influenza B (Victoria)−−Influenza B (Yamagata)−−Parainfluenza virus 1--4 (patient isolate)\*−−Respiratory syncytial virus A and B−−Human rhinovirus A 16−−Human rhinovirus A 90−−Human rhinovirus A 8−−Human rhinovirus B 5−−Human rhinovirus B 42−−Human rhinovirus C−−Enterovirus 68−−Human metapneumovirus A1 and B2−−Adenovirus type 1, 4, and 34−−  **Avian respiratory viruses**A/Anhui/1/13 (H7N9)++A/Chicken/Germany/79 "Taucha" (H7N7)+−A/Chicken/Brescia/19/02 (H7N7)+−A/Chicken/Germany/R28/03 (H7N7)+−A/*Cygnus olor*/Germany/R1377/07 (H5N1)−−A/Chicken/Egypt/0833-NLQP/2008 (H5N1)−−A/Chicken/Vietnam/P78/05 (H5N1)−−Newcastle disease virus clone 30−−Infectious laryngotracheitis virus U76−−Infectious laryngotracheitis virus (A489)−−Infectious bronchitis M41−−

Two RT-RPA assays were developed. As no program or strict rules for designing RPA primers and probe were available, three forward primers (FPs), three reverse primers (RPs), and one exo-probes (exo-Ps) were tested for each assay to select the combination producing the highest RT-RPA assay analytical sensitivity ([Table 2](#tbl0010){ref-type="table"} ). Oligonucleotides were synthesized by TIB MOLBIOL (Berlin, Germany).Table 2Sequence of primers and exo-probes for H7N9 RT-RPA assays.NameSequence 5′--3′Amplicon size (nt)H7-RPA-FPCACAGCAAATACAGGGAAGAGGCAATGCAAAATAG121H7-RPA-RPGAAGTATGAAACATGATGCCCCGAAGCTH7-RPA-PCAAAGTATCACATCTT (BHQ1-dT)(THF)(FAM-dT)AGCCGCTGCTTAGTTTGACTGGGTCAATCTG-PH  N9-RPA-FPCAGAGGGAAACACTCAAACGGAACAATACAC129N9-RPA-RPCTAGTACTTGACCACCCAATGCATTCCACCCTGCN9-RPA-PCTGCTGTTGTACAC(BHQ1-dT)(THF)(FAM-dT)GGGCGGTGATGATAGTGGCCAGCTTATCAG-PH[^1]

3.2. Diagnostics-in-a-Suitcase {#sec0025}
------------------------------

To simplify the use of H7N9 RT-RPA assays at the site of an outbreak, DiaS ([Fig. 1](#fig0005){ref-type="fig"} ) was created. DiaS contains all reagents and equipment necessary for performing H7N9 RT-RPA assays. A case of size 56 cm × 45.5 cm × 26.5 cm (ZARGES GmbH, Weilheim, Germany) is lined with foam at its base to act as a shock absorber during transport. A PVC layer is attached to the foam, into which indents are cut and sealed to render them watertight ([Fig. 2](#fig0010){ref-type="fig"} ). These indents house the equipment needed to perform the sample processing and amplification reactions: a tube scanner (Twista, TwistDx, Cambridge, UK), disinfectant wipes (Pursept^®^-A Xpress, Merz Consumer Hygiene GmbH, Luetjenburg, Germany), a waste container (Sarstedt, Nuembrecht, Germany), a vortex (lab-Dancer, IKA^®^, Staufen, Germany), a Sprout^®^ Minicentrifuge (OMNILAB, Bremen, Germany), and two easily refillable Pipette Tip boxes (BRAND, Wertheim, Germany), in addition to a micro-tube rack, scissors, and a magnetic stand (Beckman Coulter, Krefeld, Germany). The lid of the case contains a box for gloves, an FFP3 mask, protection goggles, 1--10- and 10--100-μl automatic micropipettes (Eppendorf AG, Hamburg, Germany), marker and boxes for storage buffers, and RPA kits. A solar panel and a power pack (Yeti 150 set, GOALZERO, South Bluffdale, UT, USA) provide the energy needed.Fig. 1Diagnostics-in-a-Suitcase. It contains all equipment and reagents for performing the RT-RPA assay.Fig. 2Layout of the PVC layer of the Diagnostics-in-a-Suitcase. All measurements are in centimeters. The inside of the bold line represents the cutouts whereas the dotted lines represent the distance between two points.

3.3. Workflow in the DiaS {#sec0030}
-------------------------

The workflow consisted of total viral nucleic acid extraction using magnetic beads (Dynabeads^®^ SILANE viral NA, Life Technologies, Darmstadt, Germany) according to the manufacturer\'s instructions with few modifications. In summary, 200 μl of the sample was incubated with 50 μl of proteinase K and 300 μl of lysis buffer for 5 min at room temperature. Thereafter, 150 μl of isopropanol and 50 μl of Dynabeads were added and incubated for 10 min followed by two washing steps. Nucleic acid bound to the Dynabeads was left to dry for 5 min, followed by elution. The total time needed for the extraction was 30 min. For the RT-RPA assay, the ready-to-use TwistAmp™ RT exo (TwistDx, Cambridge, UK) was used as described [@bib0180]. Briefly, RPA primers (420 nM), the probe (120 nM), 45 μl of rehydration buffer containing 14 mM Mg acetate, and 5 μl of extracted RNA were added. The tube was closed and mixed well, and then placed in the tube scanner for 10 min at 42 °C. The total time for the RT-RPA test was 15 min. All pipetting steps were performed in the suitcase area. Surfaces outside of the suitcase were not used.

3.4. Analytical sensitivity and specificity of H7N9 RT-RPA assays {#sec0035}
-----------------------------------------------------------------

In vitro transcribed HA and NA RNAs of the H7N9 A/Anhui/1/2013 virus (accession numbers: EPI439507, EPI439509) were provided by the Friedrich-Loeffler-Institute, Greifswald-Insel Riems, Germany [@bib0200]. To determine the analytical sensitivity of RT-RPA assays, RNA molecular standard quantities ranging from 10^7^ to 10^1^ RNA molecules/μl were used. The RT-RPA assay was performed using the ready-to-use TwistAmp™ RT exo (TwistDx, Cambridge, UK) as described before [@bib0200]. Using PRISM (Graphpad Software Inc., San Diego, CA, USA), the threshold time was plotted against molecules detected and a semilog regression was calculated. To determine the limit of detection at 95% probability, a probit regression was performed using STATISTICA (StatSoft, Hamburg, Germany). The specificity of RT-RPA assays was determined by testing six H7N9-negative chicken samples and a reference human genome. In addition, the cross-reactivity was tested using the viral nucleic acids listed in [Table 1](#tbl0005){ref-type="table"}. For comparison, H7N9 real-time RT-PCR was performed as previously described [@bib0205].

4. Results {#sec0040}
==========

Two RT-RPA assays were designed for the detection of avian influenza A (H7N9) virus. Two molecular in vitro transcribed RNA standards (H7 and N9) were implemented to evaluate both RT-RPA assays. A dilution range of 10^7^--10^1^  molecules/μl of the RNA H7 and N9 molecular standards was used to select the RT-RPA primer and probe combination to produce the highest assay analytical sensitivity. RPA primers and exo-Ps listed in [Table 2](#tbl0010){ref-type="table"} yielded an analytical sensitivity between 10 and 100 RNA molecules for the H7 and N9 RT-RPA assays, respectively ([Fig. 3](#fig0015){ref-type="fig"} ).Fig. 3Analytical sensitivity of H7N9 RT-RPA assays. (A) The H7 and (B) the N9 RT-RPA assays. Fluorescence development via real-time detection using a dilution range of 10^7^--10^1^ RNA molecules/μl of the H7 and N9 RNA molecular standards (graph generated by ESEquant tube scanner studio software). The sensitivities were 10 and 100 RNA molecules for the H7 (A) and the N9 (B) RT-RPA assays, respectively. The reverse transcription took place in the first minute. To increase the sensitivity, a mixing step was performed after 3 min (no fluorescence signal was detected). 10^7^ represented by black line; 10^6^, gray; 10^5^, red; 10^4^, blue; 10^3^, green; 10^2^, cyan; 10^1^, dark khaki; and negative control, orange. (For interpretation of the references to color in this text, the reader is referred to the web version of the article.)

Using the data of eight RT-RPA runs of RNA molecular standard serial dilutions, a semilog regression ([Fig. 4](#fig0020){ref-type="fig"} ) and probit regression analysis ([Fig. 5](#fig0025){ref-type="fig"} ) were carried out. The run times for both assays were between 2 and 7 min ([Fig. 4](#fig0020){ref-type="fig"}). The limits of detection in 95% of cases were calculated to be 14 ([Fig. 5](#fig0025){ref-type="fig"}A) and 179 ([Fig. 5](#fig0025){ref-type="fig"}B) RNA molecules detected for the H7 and the N9 RT-RPA assays, respectively. Both the H7 and N9 RT-RPA assays were specific. They detected neither viral nucleic acids of other respiratory viruses ([Table 1](#tbl0005){ref-type="table"}) nor the human or the avian genome. Unfortunately, no clinical samples were available to test the clinical sensitivity of the assay.Fig. 4Reproducibility of H7N9 RT-RPA assays. (A) H7 and (B) N9 RT-RPA assays. Semilogarithmic regression of the data collected from eight H7N9 RT-RPA test runs on the RNA molecular standard using Prism Software. Both assays yielded results between 2 and 7 min. In the H7 RT-RPA assay, 10^7^--10^2^ RNA molecules were detected in eight out of eight, and 10 in six of eight RT-RPA runs. In the N9 assay, 10^7^--10^3^ RNA molecules were detected in all RT-RPA runs, 10^2^ in seven out of eight, and 10 in two out of eight.Fig. 5Probit analysis of H7N9 RT-RPA assays. (A) H7 and (B) N9 RT-RPA assays. Probit regression analysis using STATISTICA software on the data set of the eight RT-RPA assay runs. The limit of detection at 95% probability (14 and 179 RNA molecules for the H7 and N9 RT-RPA assays, respectively) is represented by a triangle.

5. Discussion {#sec0045}
=============

The avian influenza A (H7N9) virus, which mainly infects birds, also occasionally infects humans [@bib0210]. As of 22 December 2013, 71 deaths of 166 laboratory-confirmed human cases were recorded by the World Health Organization (WHO) in restricted parts of China including Hong Kong. By 14 November 2014, the number of confirmed human cases increased to 458, 177 of which were fatalities. In addition, infected cases were reported in Taiwan and Malaysia [@bib0215], suggesting the spread of the virus to other countries as well. Thus, it is absolutely necessary to detect an H7N9 outbreak as early as possible to initiate appropriate control measures and prevent further spread among birds or transmission to humans.

Several real-time RT-PCRs were developed for sensitive detection of avian influenza (H7N9) virus [@bib0200], [@bib0205], [@bib0220]. They produced results in 50--90 min. To avoid contamination of reagents or the workplace with PCR amplicons, the preparation of the master mix, addition of the sample RNA to the mix, and the PCR reaction must be performed in separate biological safety cabinets or pipetting hoods. Moreover, real-time RT-PCR reagents must be stored in a freezer at −20 °C. Therefore, real-time RT-PCR is not easy to use at the point of need or in the field.

The detection of avian influenza (H7N9) virus was also performed by reverse transcription-loop-mediated isothermal amplification (RT-LAMP) [@bib0225], [@bib0230], [@bib0235], [@bib0240], [@bib0245]. RT-LAMP amplification was achieved at 60 °C in \>30 min, and readout was done with the naked eye or SYBR Green-based detection. However, RT-LAMP needs six to 12 primers for the amplification of the H7 and N9 genes, which are not easy to design especially for highly variable RNA viruses. By contrast, the H7N9 RT-RPA assays developed in this study were very fast (2--7 min). They were operated at a single temperature (42 °C), and only four primers and two exo-Ps were needed for the amplification and detection of two genes (H7 and N9). Moreover, the analytical sensitivity and specificity of the RT-RPA assays were as good as that of the published real-time-RT-PCR [@bib0205].

To allow for the use of the RT-RPA assay at quarantine stations, ports, or the site of outbreak, the developed DiaS contains the complete equipment and reagents needed to perform on-site RPA-based diagnostic test. DiaS has the same size as a standard suitcase, which is easy to carry, transport, and ship. The DiaS currently costs around 5000 euro. The system can be used with a solar panel and/or power pack as a source of energy for easy use in low-resource settings. All RT-RPA reagents and oligonucleotides can be stored at ambient temperature for up to 3 months. RNA extraction is achieved by a magnetic-bead-based method, which reduces the risk of environmental contamination because no centrifugation step is needed. Six samples can be tested at the same time, in addition to negative and positive controls. Kits for up to 98 samples can be stored in the DiaS. The DiaS storage box can be refilled whenever needed. Results are displayed as positive or negative on the screen of the tube scanner without the need of a laptop. Overall, nine pipetting steps are needed. Further improvements to reduce the pipetting steps could be to include lyophilized RPA primers and probe into the RPA pellet, to employ a multiplex RT-RPA assay, and to apply simple non-purification lysis. In addition, generic influenza RT-RPA assays for detection of influenza type A and B as well as H5N1 are being developed, but they have not yet been included [@bib0250].

In conclusion, the developed DiaS represents a portable, rapid, and simple platform for the detection of avian influenza A (H7N9) virus at the point of need and in low-resource settings. DiaS depends on the RPA technique for identifying the RNA of the H7N9 virus, which can be optimized for the detection of the genome of other infectious agents as well.
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[^1]: H7-RPA-FP and H7-RPA-RP are forward and reverse RPA primers for the H7 RT-RPA assay; N9-RPA-FP and N9-RPA-RP are forward and reverse RPA primers for the N9 RT-RPA assay; H7-RPA-P and N9-RPA-P are exo-probes; BHQ1-dT, thymidine nucleotide carrying Black Hole Quencher-1; THF, tetrahydrofuran spacer; FAM-dT, thymidine nucleotide-carrying fluorophore; nt, nucleotides.
